FDA
-
-
-
-
-
-
-
Ocera Therapeutics Reports Second Quarter 2017 Financial Results
-
-
-
-
-
-
-
After-Hours Stock Movers 04/12: (OCRX) (AAOI) (HBI) Higher; (SRNE) (DMPI) (PIR) Lower (more...)
-
-
-
-
-
-
-
Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy
-
-
-
-
-
-
-
Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis
-
322,976 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

